Sanofi supports phase 3 of ADA’s Therapeutic Inertia program. The main goal of phase 3 is to promote the measurable adoption of evidence-based practices, strategies, programs and tools that address key barriers associated with therapeutic inertia in diabetes care, leading to improved, timely treatment modification and improved overall glycemic control in adult patients with type 2 diabetes. Sanofi also supported the American Diabetes Association’s 100 Years of Insulin, a year-long campaign that focused on awareness, education and promoting activities that build community.

View website